Hyperlactataemia syndromes associated with HIV therapy

Lancet Infectious Diseases

Volumn 3, Issue 6, 2003, Pages 329-337

  Ogedegbe, Anthony Emmanuel O ^a   Thomas, David L ^a   Diehl, Anna Mae ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ASCORBIC ACID; BICARBONATE; CARNITINE; DIDANOSINE; DNA POLYMERASE; HYDROXYUREA; LACTIC ACID; LAMIVUDINE; RIBAVIRIN; RIBOFLAVIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THIAMINE; UBIQUINONE; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ABDOMINAL DISCOMFORT; COMA; DRUG MECHANISM; FATTY LIVER; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTIC ACIDOSIS; LIVER TOXICITY; METABOLIC ACIDOSIS; MULTIPLE ORGAN FAILURE; NAUSEA; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT REDUCTION; CHEMICALLY INDUCED DISORDER; SYNDROME;

ACIDOSIS, LACTIC; ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; SYNDROME;

EID: 0037527547     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(03)00654-6     Document Type: Review

References (105)

1. Gerad Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000; 14: 2723-30.
2. John M, Moore CB, James IR, et al. Chronic hyperlactataemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 151: 717-23.
3. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV cohort Study. Clin Infect Dis 2001; 33: 1931-37.
4. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16: 1341-49.
5. Moyle G. Hyperlactatemia and lactic acidosis. Should routine screening be considered? AIDS Read 2002; 12: 344-48.
6. Brinkman K. Editorial response: hyperlactataemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin Infect Dis 2000; 31: 167-69.
7. Brinkman K. Management of hyperlactataemia: no need for routine lactate measurements. AIDS 2001; 15: 795-97.
8. John M, Mallal S. Hyperlactataemia syndromes in people with HIV infection. Curr Opin Infect Dis 2002; 15: 23-29.
9. Konig H, Behr E, Lower J, Kurth R. Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type 1 reverse transcriptase and DNA polymerase gamma. Antimicrob Agents Chemother 1989; 33: 2109-14.
10. White EL, Parker WB, Macy LJ, et al. Comparison of the effect of carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases. Biochem Biophys Res Commun 1989; 161: 393-98.
11. Simpson MV, Chin CD, Keilbaugh SA, Lin T-S, Prusoff WH. Studies on the inhibition of mitochondrial DNA-replication by 3′-azido-3′deoxythymidine and other dideoxynucleoside analogues which inhibit HIV-1 replication. Biochem Pharmacol 1989; 38: 1033-36.
12. Chen CH, Cheng YC. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem 1989; 255: 11847-52.
13. Chen C, Vasquez-Padua M, Cheng Y. Effect of anti-human immunodeficiency virus nucleoside analogues on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991; 39: 625-28.
14. Benbrik E, Chariot P, Bonavaud S, et al. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci 1997; 149: 19-25.
15. Masini A, Scotti C, Calligaro A, et al. Zidovudine-induced experimental myopathy: dual mechanism of mitochondrial damage. Neurol Sci 1999; 166: 131-40.
16. Pan-Zhou XR, Cui L, Zhou XJ, Sommadossi JP, Darley-Usmar VM. Differential effects of antiretroviral nucleoside analogues on mitochondrial function in HepG2 cells. Antimicrob Agents Chemother 2000; 44: 496-503.
17. Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiviral nucleoside analogues and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276: 40847-57.
18. Birkus G, Hitchcock MJM, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46: 716-23.
19. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16: 2165-73.
20. Brinkman K, ter Hofstede JM, Burger DM, Smeitink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-44.
21. White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect 2001; 77: 158-73.
22. Freiman JP, Helfert KE, Hamrell MR, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 1993; 7: 379-85.
23. Chattha G, Arieff AI, Cummings C, Tierney LM. Lactic acidosis complicating acquired immunodeficiency syndrome. Ann Intern Med 1993; 118: 37-39.
24. Mokrzycki M, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 2000; 30: 198-200.
25. Miller K, Cameron M, Wood L, Dalakas M, Kovacs J. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000; 133: 192-96.
26. Coghlan ME, Sommadossi J-P, Jhala NC, Many WJ, Saag MS, Johnson VA. Symptomatic lactic acidosis in hospitalised antiretroviral treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 2001; 33: 1914-21.
27. Chariot P, Drogou I, de Lacroix-Szmania I, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999; 30: 156-60.
28. Bleeker-Rovers CP, Kadir SW, van Leusen R, Richter C. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient. Neth J Med 2000; 57: 190-93.
29. Johri S, Alkuja S, Siviglia G, Soni A. Steatosis lactic acidosis syndrome associated with stavudine and lamivudine therapy. AIDS 2000; 14: 1286-87.
30. Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002; 34: 838-46.
31. Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analogue antiretroviral therapy. Am J Gastroenterol 1995; 90: 1433-36.
32. Bissuel F, Bruneel F, Habersetzer F, et al. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med 1994: 235: 367-71.
33. Hofstede HJM, de Marie S, Foudraine NA, Danner SA, Brinkman K. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000; 11: 611-16.
34. Lonergan JL, Behling C, Pfander H, Hassanein TT, Mathews WC. Hyperlactataemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31: 162-66.
35. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel. J Acquir Immun Defic Syndr 2002; 31: 257-75.
36. Moyle G. Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism? Drug Saf 2000; 23: 467-81.
37. Barlie M, Valenti D, Hobbs GA, et al. Mechanisms of toxicity of 3′-azido-3′-deoxythyrnidine. Its interaction with adenylate kinase. Biochem Pharmacol 1994; 4: 1405-12.
38. Barile M, Valenti D, Passarella S, Quagliariello E. 3′- Azido-3′-deoxythmidine uptake into isolated rat liver mitochondria and impairment of ADP/ATP translocator. Biochem Pharmacol 1997; 53: 913-20.
39. Barile M, Valenti D, Quagliariello E, Passarella S. Mitochondria as cell targets of zidovudine (zidovudine). Gen Pharmacol 1998; 31: 531-38.
40. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337: 508-10.
41. Mhiri C, Baudrimont M, Bonne G, et al. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol 1991; 29: 606-14.
42. Gaou I, Malliti M, Guimont MC, et al. Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. J Pharmacol Exp Ther 2001; 297: 516-23.
43. Gerschenson M, Nguyen VT, St Claire MC, et al. Chronic stavudine exposure induces hepatic mitochondrial toxicity in adult Erythrocebus patas monkeys. J Hum Virol 2001; 4: 335-42.
44. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 192-97.
45. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of azidothymidine in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 Infection. Ann Intern Med 1990; 112: 727-37.
46. Lambert JS, Seidlin M, Reichman RC, et al. 2′-3′- dideoxyinosine in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl J Med 1990; 322: 1333-40.
47. Cooley TP, Kunches LM, Saunders CA, et al. Once daily administration of 2′,3′-dideoxyinosine in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a phase I trial. N Engl J Med 1990; 322: 1340-45.
48. Schindzielorz A, Pike I, Daniels M, Pacelli L, Smaldone L. Rates and risk factors for adverse events associated with didanosine in the expanded access program. Clin Infect Dis 1994; 19: 1076-83.
49. Browne MJ, Mayer KH, Chafee SB, et al. 2′,3′- Didehydro-3′-deoxythymidine in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 1993; 167: 21-29.
50. Murray HW, Squires KE, Weiss W, et al. Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089. J Infect Dis 1995; 17 (suppl 2): 123-30.
51. Petersen EA, Ramirez-Ronda CH, Hardy WD, et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis 1995; 171 (suppl 2): 131-39.
52. Skowron G. Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J Infect Dis 1995; 171 (suppl 2):113-17.
53. van Leeuwen R, Lange JM, Hussey EK, et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992; 6: 1471-75.
54. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination in antiretroviral treatment-naive patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 1996; 276: 118-25.
55. Staszewski S, Hill AM, Bartlett J, et al. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS 1998; 12: F197-202.
56. Saag MS, Sonnerborg A, Torres RA, et al. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. AIDS 1998; 12: F203-9.
57. Kumar PN, Sweet DE, McDowell JA, et al. Safety and pharmokinetics of abacavir (1592U89) following oral administration of escalating doses in human immunodeficiency virus HIV-infected adults. Antimicrob Agents Chemother 1999; 43: 603-08.
58. Staszewski S, Keiser P, Montaner J, et al. CNAAB3005 International Study Team. Abacavir-lamivudinezidovudine versus indinavir-lamivudine-zidovudine in antiretroviral-naive adults. JAMA 2001; 9: 1155-63.
59. Kessler HA, Johnson J, Follansbee S, et al. Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1. Clin Infect Dis 2002; 34: 535-42.
60. Deeks SG, Barditch-Crovo P, Lietman PS, et al. Safety, phamarcokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy) propyl]adenenine, a novel anti-human immunodeficiency virus therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998; 42: 2380-84.
61. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45: 2733-39.
62. Corcuera T, Alonso MJ, Picazo A, et al. Hepatic morphological alterations induced by zidovudine (ZDV) in an experimental model. Pathol Res Pract 1996; 192: 182-87.
63. Gallant J, Staszewski S, Pozniak A, et al. Favourable lipid and mitochondrial DNA profile for tenofovir disoproxil fumarate compared to stavudine in combination with lamivudine and efavirenz in antiretroviral therapy naïve patients: a 48 week interim analysis. 42nd ICAAC. September 27-30, 2002, San Diego, CA. Abstract late breaker 2 (slide session).
64. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130-39.
65. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001; 276: 37514-19.
66. Sutinen J, Hakkinen AM, Westerbacka J, et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002; 16: 2183-93.
67. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6: 513-19.
68. Pessayre D, Haouzi D, Fau D, Robin MA, Mansouri A, Berson A. Withdrawal of life support, altruistic suicide, fratricidal killing and euthanasia by lymphocytes: different forms of drug-induced hepatic apoptosis. J Hepatol 1999; 31: 760-70.
69. McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 1099-105.
70. Richardson FC, Engelhardt JA, Bowsher RR. Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration. Proc Natl Acad Sci USA. 1994; 91: 12003-07.
71. Garcia de la Asuncion JG, del Olmo ML, Sastre J, et al. zidovudine treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Invest 1998; 102: 4-9.
72. Garcia de la Asuncion JG, del Olmo ML, Sastre J, Millian A, Palliardo FV, Vina J. Zidovudine causes oxidation of mitochondrial DNA in mouse liver. Hepatology 1999; 29: 985-87.
73. Yamaguchi T, Katoh I, Kurata S. AZT causes functional and structural destruction of mitochondria, glutathione deficiency and HIV-1 promoter sensitisation. Eur J Biochem 2002; 269: 2782-88.
74. Lewis W, Copeland WC, Day BJ. Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab Invest 2001; 6: 777-90.
75. Piccolo G, Banfi P, Azan G, et al. Biological markers of oxidative stress in mitochondrial myopathies with progressive external ophthalmoplegia. J Neurol Sci 1991; 105: 57-60.
76. Esposito LA, Melov S, Panov A, Cottrell BA, Wallace DC. Mitochondrial disease in mouse results in increased oxidative stress. Proc Natl Acad Sci. USA 1999; 96: 4820-25.
77. Wei YH, Lu CY, Wei CY, Ma YS, Lee HC. Oxidative stress in human ageing and mitochondrial disease-consequences of defective mitochondrial respiration and impaired antioxidant enzyme system. J Physiol 2001; 44: 1-11.
78. Lafeullade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HCV/HIV coinfection. Lancet 2001; 337; 280-81.
79. Kakuda T, Brinkman K. Mitochondrial toxic effects and ribavirin. Lancet 2001; 357: 1802-03.
80. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silberman B, Sogni P. Mitochondrial toxic effects and ribavirin. Lancet 2001; 357: 1803-04.
81. Guyader D, Poinsignon Y, Cano Y, Saout L. Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C. J Hepatol 2002; 37: 289-91.
82. Johns Hopkins Hospital AIDS Service website: http://www.hopkins-aids.edu. (Accessed May 6, 2003).
83. Hill JB, Sheffield JS, Zeeman GG, Wendel GD. Hepatotoxicity with antiretroviral treatment of pregnant women. Obstet Gynecol 2001; 98: 909-11.
84. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Inf 2002; 78: 58-59.
85. Public Health Service task force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. August 30, 2002: 6. National Institutes of Health.
86. Vir S, Love AHG, Thompson W. Riboflavin status during pregnancy. Am J Clin Nutr 1981; 34: 2699-705.
87. Morris AAM, Taanman J-W, Blake J, et al. Liver failure associated with mitochondrial DNA depletion. J Hepatol 1998; 28: 556-63.
88. Mandel H, Hartman C, Berkowitz D, Elpeleg ON, Manov I, Iancu TC. The hepatic mitochondrial DNA depletion syndrome: ultrastructural changes in liver biopsies. Hepatology 2001; 34: 776-84.
89. Chen X, Goudsmit J, Van der Kuyl A. Lack of correlation between length variation in the DNA polymerase gamma gene CAG repeat and lactic acidosis or neuropathy during antiretroviral treatment. AIDS Res Hum Retroviruses 2002; 18: 531-34.
90. Marcus K, Truffa M, Boxwell D, Toerner J. Recently identified adverse events secondary to NRTI therapy in HIV-infected individuals: cases from the FDA's adverse event reporting system. Ninth conference on retroviruses and opportunistic infections. Seattle, Washington, USA; February 24-28, 2002. Abstract LB14.
91. Department of health and human services guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 4, 2002: pages 16-17.
92. Arici C, Tebaldi A, Quinzan GP, Maggiolo F, Ripamonti D, Suter F. Severe lactic acidosis and thiamin administration in an HIV-infected patient on HAART. Int J STD AIDS 2001; 12: 407-09.
93. Luzatti R, Del Brove P, Di Perri G, Luzzani A, Concia E. Riboflavin and severe lactic acidosis. Lancet 1999; 353: 901-02.
94. Brinkman K, Vrouenraets S, Kauffman R, Weigel H, Frissen J. Treatment of nucleoside-analogue reverse transcriptase inhibitor-induced lactic acidosis. AIDS 2000; 14: 2801-02.
95. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346: 811-20.
96. McComsey G, Tan DJ, Lederman M, Wilson E, Wong LJ. Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS 2002; 16: 513-18.
97. Ong JP, Younossi Z, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed non-alcoholic fatty liver disease. Liver 2001; 21: 266-71.
98. Clouston AD, Jonsson JR, Purdie DM, et al. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001; 34: 314-20.
99. Adinolfi LE, Gambardella M, Andreana A, Tripodi M-F, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
100. Lai MMC. Hepatitis C virus proteins: direct link to hepatic oxidative stress, steatosis, carcinogenesis and more. Gastroenterology 2002; 122: 568-71.
101. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-75.
102. Falck-Ytter Y, Younossi Z, Marchesini G, McCullough AJ. Clinical features and natural history of non-alcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17-26.
103. Angulo P. Non-alcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
104. Tilg H, Diehl AM. Cytokines in alcoholic and non-alcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-76.
105. Chitturi S, Farrel GC. Etiopathogenesis of non-alcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27-41.